GSK’s ViiV Healthcare has shared clinical data on three potential long-acting HIV treatments, providing a look at how its ...

ViiV Healthcare's EMBRACE study shows VH109 with CAB LA effectively suppresses HIV. The company also reports promising early ...

Gilead plans to go straight to Phase III studies for once-yearly lenacapavir, while GSK and Viiv will push forward with their ...

Bearish flow noted in GSK (GSK) Pharma with 5,611 puts trading, or 3x expected. Most active are Mar-25 36.5 puts and 3/14 weekly 39.5 calls, with total volume in those strikes near 6,100 contracts.

New real-world and implementation study data highlight the efficacy of ViiV’s long-acting injectables for HIV prevention and ...

GSK (GSK) announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer (PFE) and Shionogi (SGIOY) as ...

Every year, amid Women’s History Month, March 8 marks International Women’s Day—a day dedicated to both honoring past efforts ...

Atria Investments Inc cut its holdings in GSK plc (NYSE:GSK – Free Report) by 7.6% in the fourth quarter, according to the ...

This summer is likely to be an emotional time for many in Ulverston. In June, 75 years of manufacturing history will come to an end in the town when pharmaceutical giant GSK closes its factory at ...